New episode ποΈ Scott Howell & Mark Hansan talk with Jonathan Blum on the future of U.S. drug policyβIRA trade-offs, 2026 Part D redesign, M3P, and balancing affordability & innovation. Must-listen for #access#coverage#drugpricing. π§ https://t.co/Bzxlf6Pc18
New episode β live from ACCESS US 2025!
Can we improve drug affordability without stalling innovation?
Scott Howell & Mark Hansan lead a powerful convo w/ leaders from BMS, ICER, NPC & Accenture on pricing, PBMs, AI & whatβs next for patient access.
https://t.co/a48VtsbplQ
Episode 29 of the podcast is now live! We called this episode The Domino Effect because so many of the challenges with #drugaccess and #affordability can be traced back to one foundational issue: benefit design. Listen now: https://t.co/8QXtJ3NzV8
We've got an exciting new episode coming your way next week--while you wait, don't miss our April episode with Brian Reid, MS, editor at Cost Curve. Listen here: https://t.co/Bu7y1UlJCi
Don't forget! This month we released an episode with #BrainReid of #CostCurve digging into his approach towards #healthcare and #drugpricing reporting. Listen here: https://t.co/Bu7y1UlJCi
NEW EPISODE: #DrugPricing is of the most debated β and misunderstood β issues in #healthcare. In our latest episode, we talk with Brian Reid, MS, Principal at Reid Strategic and editor of #CostCurve, one of the smartest voices cutting through the noise. https://t.co/4IqyNqWEl1
New episode! Check out Mark and Scott's conversation about patient access with Sarah Emond, MPP, President and CEO of ICER. https://t.co/ydIoaHf70J #patientaccess
NEW EPISODE ALERT
Sarah Emond, MPP, President & CEO of the Institute for Clinical and Economic Review (ICER), joins me and Scott Howell for a timely discussion on the challenges and opportunities in drug pricing and patient access.
https://t.co/ydIoaHezbb
The Prescription for Better Access podcast (@RX4BetterAccess) interviewed ICER's President and CEO @sarahkemond. They discussed discussed ICER's new annual Launch Price and Access Report, the role of employers in drug pricing, and more.
Listen now! https://t.co/NeQqIRHN8E
New podcast episode! Stacie Dusetzina, Ph.D., a leading health economist from Vanderbilt University Medical Center discusses the critical healthcare and policy trends shaping 2025. https://t.co/PAbsI30Eqj
Check out our latest conversation with Stacie Dusetzina, PhD from Vanderbilt University about critical healthcare and policy trends shaping 2025! #healthcare#patientaccess https://t.co/PAbsI30Eqj
Mark and Scott interview Stacie Dusetzina, Ph.D., of Vanderbilt University about the state of drug pricing and more for 2025. Tune in here to listen: https://t.co/PAbsI30Eqj #patientaccess#drugpricing
Check out the new episode! Mark and Scott talk to Stacie Dusetzina of #VanderbiltHealth about her outlook for 2025. Listen to the episode here: https://t.co/PAbsI30Eqj
New episode! Mark Hansan and Scott Howell wrap up 2024 with Stacie Dusetzina, PhD, Professor at #VanderbiltUniversity and researcher and expert in pharmaceutical and health policy. Stacie helps us better understand the policy outlook for 2025 and beyond. https://t.co/PAbsI30Eqj
New episode! We explore the affordability and access environment for cell and gene therapies Tune in to hear Alicia Silver (Gedan), Head of Cell and Gene Therapy at #ADVIHealth, and Eric Faulkner, President of Passage Health Associates.
https://t.co/CYQEF7Tic0